Abstract
Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Current Pharmaceutical Design
Title:Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Volume: 20 Issue: 14
Author(s): Gilles Mees, Mike Sathekge, Alex Maes and Christophe Van de Wiele
Affiliation:
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Abstract: Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.
Export Options
About this article
Cite this article as:
Mees Gilles, Sathekge Mike, Maes Alex and Wiele Van de Christophe, Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113196660662
DOI https://dx.doi.org/10.2174/13816128113196660662 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Possibility of Enhanced Risk of Retinal Angiogenesis in Athletes with Pre- Existing Retinal Situation Abusing Erythropoietin Doping: A Hypothesis
Current Drug Safety Regulation of Intracellular Cardiomyocyte Calcium Stores by Peptides: A New Approach to Cardiac Protection
Current Medicinal Chemistry Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy The Potential Roles of Gamma-Glutamyltransferase Activity in the Progression of Atherosclerosis and Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry Chemokines in Cardiovascular Remodeling: Clinical and Therapeutic Implications
Current Molecular Medicine The Role of Trimetazidine After Acute Myocardial Infarction
Current Vascular Pharmacology Editorial: [Hot Topic: Non-Analgesic Effects of Opioids]
Current Pharmaceutical Design A Unique Case Series of Novel Biomarkers of Cardiac Damage in Cyclists Completing the 4800 km Race Across America (RAAM)
Current Medicinal Chemistry Mitochondria-Targeted Drugs
Current Molecular Pharmacology P2Y12 Receptor Antagonists in Acute Coronary Syndrome: Clinical Implications of Pharmacologic and Pharmacogenetic Differences
Recent Patents on Cardiovascular Drug Discovery The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design Patent Selections:
Recent Patents on Biomarkers Lipid Lowering Agents, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Coronary Microcirculation in Heart Failure with Preserved Systolic Function
Current Pharmaceutical Design Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Current Signal Transduction Therapy Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction
Current Cardiology Reviews